Evolocumab reduces cardiovascular events in diabetes without known atherosclerosis
Evolocumab cuts heart events in high-risk diabetes patients
This prespecified subgroup analysis of a phase 3 RCT evaluated evolocumab added to statin therapy in 3655 high-risk patients with type 2 dia…
Adding evolocumab to statins reduced heart attacks and strokes by about 30% in high-risk diabetes patients without known heart disease.
Phase 4 study of evolocumab safety and tolerability in renal transplant recipients
Can a new cholesterol drug help kidney transplant patients without causing harm?
This Phase 4 study evaluated the safety and tolerability of evolocumab, a PCSK-9 inhibitor, in renal transplant recipients at three hospital…
A new cholesterol injection kept kidney transplant patients safe for over two years without serious side effects, offering a potential alter…
Corrective re-analysis suggests Lp(a) reduction accounts for 57-70% of PCSK9 inhibitor benefit in ASCVD.
Re-analysis suggests most PCSK9 inhibitor benefit comes from lowering Lp(a)
This Phase 3 corrective re-analysis of cardiovascular outcomes trial data in secondary prevention populations with ASCVD evaluated the role …
Researchers re-analyzed data from Phase 3 trials of alirocumab and evolocumab in patients with atherosclerotic cardiovascular disease. They …